What is Blau Syndrome?

Blau Syndrome is a rare genetic disorder characterized by inflammatory arthritis, uveitis (eye inflammation), and skin rash. It is caused by mutations in the NOD2 gene.

How big is the Blau Syndrome Market?

The global Blau Syndrome Market size was estimated at USD 7.9 Million in 2023 and is expected to reach USD 25.0 Million in 2033.

What is the Blau Syndrome Market growth?

The global Blau Syndrome Market is expected to grow at a compound annual growth rate of 12.2%. From 2024 To 2033

Who are the key companies/players in the Blau Syndrome Market?

Some of the key players in the Blau Syndrome Markets are Pfizer, Salix Pharmaceuticals, Novartis AG, Mylan N.V, Himca pharma plc, ONCODESIGN, Amgen Inc, Abbvie Inc, Alkem labs, Accord healthcare, Zydus Pharmaceuticals, Centogene AG, Teva Pharmaceuticals, Amneal Pharmaceutical Inc.

What factors contribute to the prevalence of Blau Syndrome?

The prevalence of Blau Syndrome is influenced by genetic predisposition, with the condition typically inherited in an autosomal dominant pattern. However, sporadic cases can also occur.

How is Blau Syndrome diagnosed?

Diagnosis of Blau Syndrome typically involves a thorough clinical evaluation, genetic testing to identify mutations in the NOD2 gene, and imaging studies to assess joint and ocular inflammation.

What treatment options are available for Blau Syndrome?

Treatment approaches for Blau Syndrome aim to manage symptoms and may include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents targeting inflammatory pathways.

Global Blau Syndrome Market by Therapeutic Areas (Skin Rash, Inflammation), By Route of Administration (Oral, Parenteral, Topical), By End User (Hospitals, Home healthcare, Specialty clinics), By Distribution Channel (Hospital pharmacy, Online pharmacy, Retail pharmacy), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: March 2024
Report ID: 74392
Number of Pages: 332
Format:

- Pfizer Inc Company Profile
- Salix Pharmaceuticals
- Novartis AG Company Profile
- Mylan N.V
- Himca pharma plc
- ONCODESIGN
- Amgen Inc
- AbbVie Inc. Company Profile
- Alkem labs
- Accord healthcare
- Zydus Pharmaceuticals
- Centogene AG
- Teva Pharmaceuticals
- Amneal Pharmaceutical Inc
Settings

Related Reports

Our Clients

Inquiry Before Buying

Report ID 74392
Published Date March 2024
Rating
- ★★★★★
  
  ★★★★★
- (96)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)